Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Clinical Resources: LLUMC Investigational Drug Service »Desiree Wallace, Pharm.D. »Objectives: • To describe the availability of the IDS for research on campus • To discuss how one can collaborate and access the IDS to enhance research activities 2016 Research Affairs Symposium October 21, 2016 LLUMC Department of PharmacyTrial Center IDS Overview » Activities centralized in UH Central Hospital Pharmacy, 2nd floor » IDS Coverage M-F 8-4:30 (1FT Pharmacist & 1FT tech), Pharmacist Supervisor on duty after hours & weekends » Assist Coordinator (s) and Site Investigator(s) with conducting an ID protocol » InPatient: all study drugs administer in UH, CH, SH, EC must be processed through the IDS Pharmacy » OutPatient: as requested by sponsor/investigator » Any Type of Study: Open-Label, Randomized, Placebo-Controlled, Single/DoubleBlind, Investigator Initiated » Adhere to Regulations/Policies: E6 (ICH)-Good Clinical Practice Food & Drug Administration (FDA): Title 21 CFR Part 50, 56, 210 & 312 DHHS Title 45 CFR Part 46 State of CA Requirements CA Board of Pharmacy Law Institutional Policies & Procedures (421-R2, R1, Q29) LLU IRB Board Member IDS Protocol Evaluation: review feasibility of IDS participation, budget, letter of agreement, EPIC requirements, staff education Routes of Administration: intravenous, oral, topical, hazardous/chemotherapy, controlled substances Storage: in Separate area from commercially available drugs, Secured Location with Limited Access Temperature Monitoring: daily with certified calibrated device @ roomtemperature, refrigerated, frozen, excursion reporting; preferably continuous with excursion alarms & procedures established Storage Equipment: refrigerator/freezer maintained/inspected by clinical engineering Transport: Chain of Custody/Cold Chain documentation & temperature monitoring during transport Packaging/Labeling: OL or Blinded; per CA Rx Law (“Caution: New Drug—Limited by Federal law to investigational use.”); special precautions; child proof Preparation: non-aseptic, aseptic in ISO class 5 (hazardous/chemo) or laminar flow hood in USP 797 compliant facility IDS Randomization: experience with many IVRS/IWRS systems, manually, Rx generated lists Dispensing: Inpatient/Outpt EPIC/Willow/BEACON formulary build requests or treatment plan build Drug Accountability: manual paper forms or electronically; all study drug must be reconcilable Inventory: ordering, receipt, transfer, returns/compliance by subject, expiration dating Disposal: on site per SOP T-9 or return to sponsor Regulatory: maintain current Protocol/IB, IRB approval, ICD, amendments, investigator/sub-I’s, billing Monitoring, Audits and Closeout (Sponsor/CRO, FDA, DEA) Record Retention: 21 CFR 312.57c: 2 yrs after the date of approval for the indication (NDA) being investigated or not approved IDS Collaboration » Investigator may contact IDS directly for ?’s (see contact info) » CTC feasibility analysis: will help determine the need for IDS ancillary department » IDS works with CTC on LOA to Participate & Financial support » IDS will determine feasibility based on information provided by the investigator from the Sponsor & SEV (Protocol, IB, Pharmacy Manual, Operating Manual, IWRS/EDC) Conclusion »IDS resource is available to help the PI with the responsibility of Managing Investigational Drugs »IDS will collaborate with CTC, the Investigator, Coordinator & Sponsor to assure that the protocol, regulations, laws & P&P’s are followed to ensure the safety of human subjects. »IDS will ensure that all Investigational Drugs are fully managed and accounted for. Questions? Contact Information: » Desiree Wallace, Pharm.D.,RPh, Investigational Drug Pharmacist » Mayra L. Gonzalez, CPhT, IDS Pharmacy Technician » SHIPPING ADDRESS: Loma Linda University Medical Center Investigational Drug Service, Department of Pharmacy 11223 Campus Street, DOCK B Loma Linda, CA 92354 » Office: LLU School of Pharmacy, Shyrock Hall Rm 228 (909) 558-4000, ext.83773 Pager (909)558-1717,1505 or [email protected] Fax (909)558-0323 email: [email protected] » Backup: Norm Hamada, PharmD, RPh-Director of Clinical Pharmacy Services; x47386